The Alembic board on Friday said it has rejected the request by a section of small shareholders led Unifi Capital to have their representative on the board citing conflict of interests and misuse of provision under Section 151 of the Companies Act.
The regulations under the Companies Act, 2013 allow a small shareholder director on the board with the specific intent of having the interest of small shareholders represented in the decisions made by the board.
Bharti Airtel | Dena Bank | Titagarh Wagons | Jubilant Life | Kotak Mahindra Bank | Future Enterprise | Cholamandalam Investment | Vijaya Bank and Arcotech are stocks, which are in news today.
Jay Thakkar of Anand Rathi Securities is of the view that one may buy Alembic with a target of Rs 48.70.
Axis Bank | Infosys | Mindtree | Tata Steel | Canara Bank | GMR Infrastructure | Orient Green Power | Havells India | TVS Motor | Sterlite Technologies | Kalpataru Power and Ruchi Soya are stocks, which are in the news today.
Sumeet Jain of Destimoney Securities is of the view that one may buy Alembic with a target of Rs 42.80.
An establishment inspection report for Alembic‘s Karakhadi API plant from the regulator is a big positive as API is one of the main drivers for the company, says Sarabjit Kaur Nangra of Angel Broking.
Krish Subramanyam of Altamount Capital advises buying Alembic with a target of Rs 40.
Axis Bank | Bharti Infratel | Raymond | Rallis India | IDFC Bank | Syngene |Â Snowman Logistics | Alembic | Swaraj Engines | Agro Tech Foods and Gujarat Narmada Valley are stocks, which are in the news today.
Manish Sharma of derivativetradingresearch is of the view that one may buy Voltas with a target of Rs 310.
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - Hindalco, Tata Steel, JK Tyre, MRF, CEAT, DCB Bank, Dwarikesh Sugar, Triveni Engg, Balrampur Chini, HDFC, Alembic and CRISIL.
Major domestic firms such as Sun Pharma, Lupin, Glenmark, Aurobindo, Alembic and Hetero Labs figure in the list of first-time generic drug approvals released by the FDA's Office of Generic Drugs.
Sarvendra Srivastava of Phisense.com advises buying Arvind with a target of Rs 271.9.
Mehraboon Irani of Nirmal Bang Securities thinks the correction could be due to selling by foreign institutional investors (FIIs). He does not think we are likely to see a deep correction.